Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

5.32
-0.0800-1.48%
Post-market: 5.30-0.0200-0.38%19:57 EDT
Volume:8.19M
Turnover:42.51M
Market Cap:458.65M
PE:-1.41
High:5.50
Open:5.48
Low:4.98
Close:5.40
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:64.06M
Volume Ratio:0.47
T/O Rate:12.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.76
PE(LYR):-1.68

Loading ...

Eyepoint Grants Inducement Stock Options for 63,500 Shares at $13.85 Each

Reuters
·
Jul 16

Eyepoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 16

Eyepoint Inc : Stifel Initiates Coverage with Buy Rating; Target Price $40

THOMSON REUTERS
·
Jul 16

Eyepoint Pharmaceuticals Initiated at Buy by Stifel

Dow Jones
·
Jul 16

EyePoint initiated with a Buy at Stifel

TIPRANKS
·
Jul 16

EyePoint (EYPT) Adds Retina Leadership, Is The 64% Undervaluation Case Convincing?

Simply Wall St.
·
Jul 14

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jul 13

Eyepoint Appoints Tarek S. Hassan, M.d., as Chief Strategic Science Officer

THOMSON REUTERS
·
Jul 13

Press Release: Eyepoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Dow Jones
·
Jul 13

Eyepoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
Jul 08

Duravyu Pivotal Readout and Strong TKI Outlook Support Buy Rating; $43 Price Target Reiterated

TIPRANKS
·
Jul 06

Eyepoint Chief Medical Officer Ramiro Ribeiro Disposes of 4,875 Common Shares Worth $73,167.95

Reuters
·
Jul 03

Eyepoint Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 01

Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating

MT Newswires Live
·
Jul 01

EyePoint price target raised to $65 from $29 at Chardan

TIPRANKS
·
Jul 01

Jefferies Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 25

Eyepoint Pharmaceuticals Price Target Maintained with a $68.00/share by Guggenheim

Dow Jones
·
Jun 24

Guggenheim Sticks to Its Buy Rating for EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Jun 24

EyePoint shareholders approve 4.9 million-share increase to 2023 incentive plan

Reuters
·
Jun 22